Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution

被引:4
|
作者
Gultepe, Evin [1 ]
Reynoso, Francisco J. [1 ]
Jhaveri, Aditi [1 ]
Kulkarni, Praveen [1 ]
Nagesha, Dattatri [1 ]
Ferris, Craig [1 ]
Harisinghani, Mukesh [2 ]
Campbell, Robert B. [1 ]
Sridhar, Srinivas [1 ]
机构
[1] Northeastern Univ, Elect Mat Res Inst, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
关键词
biodistribution; magnetic targeting; magnetoliposomes; melanoma/skin cancer; MRI; novel drug-delivery systems; toxicology; DRUG-DELIVERY; CONTRAST AGENTS; CANCER; LIPOSOMES; NANOPARTICLES; THERAPY;
D O I
10.2217/NNM.10.84
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aims: The development of noninvasive imaging techniques for the assessment of cancer treatment is rapidly becoming highly important. The aim of the present study is to show that magnetic cationic liposomes (MCLs), incorporating superparamagnetic iron oxide nanoparticles (SPIONs), are a versatile theranostic nanoplatform for enhanced drug delivery and monitoring of cancer treatment. Materials & methods: MCLs (with incorporated high SPION cargo) were administered to a severe combined immunodeficiency mouse with metastatic (B16-F10) melanoma grown in the right flank. Pre- and post-injection magnetic resonance (MR) images were used to assess response to magnetic targeting effects. Biodistribution studies were conducted by In-111-labeled MCLs and the amount of radioactivity recovered was used to confirm the effect of targeting for intratumoral administrations. Results: We have shown that tumor signal intensities in T-2-fweighted MR images decreased by an average of 20 +/- 5% and T-2 star relaxation times decreased by 14 +/- 7 ms 24 h after intravenous administration of our MCL formulation. This compares to an average decrease in tumor signal intensity of 57 +/- 12% and a T-2 star relaxation time decrease of 27 +/- 8 ms after the same time period with the aid of magnetic guidance. Conclusion: MR and biodistribution analysis clearly show the efficacy of MCLs as MRI contrast agents, prove the use of magnetic guidance, and demonstrate the potential of MCLs as agents for imaging, guidance and therapeutic delivery.
引用
收藏
页码:1173 / 1182
页数:10
相关论文
共 50 条
  • [41] Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature
    Zhong, HZ
    Bowen, JP
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (08) : 849 - 862
  • [42] Targeting tumor vasculature: expanding the potential of DNA cancer vaccines
    Ugel, Stefano
    Facciponte, John G.
    De Sanctis, Francesco
    Facciabene, Andrea
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (10) : 1339 - 1348
  • [43] Targeting the tumor vasculature with engineered cystine-knot miniproteins
    Bonny Gaby Lui
    Nadja Salomon
    Joycelyn Wüstehube-Lausch
    Matin Daneschdar
    Hans-Ulrich Schmoldt
    Özlem Türeci
    Ugur Sahin
    Nature Communications, 11
  • [44] Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
    Kelland, Lloyd R.
    CURRENT CANCER THERAPY REVIEWS, 2005, 1 (01) : 1 - 9
  • [45] Co-targeting the tumor and its associated vasculature in glioblastoma
    Byrd, Tiara T.
    Fousek, Kristen
    Grada, Zakaria
    Aviles-Padilla, Kevin
    Bielamowicz, Kevin
    Gottschalk, Stephen
    St Croix, Bradley
    Fletcher, Bradley
    Hegde, Meenakshi
    Ahmed, Nabil
    CANCER RESEARCH, 2015, 75 (01)
  • [46] Tumor Vasculature Targeting: A Generally Applicable Approach for Functionalized Nanomaterials
    Chen, Feng
    Cai, Weibo
    SMALL, 2014, 10 (10) : 1887 - 1893
  • [47] Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting
    Alexiou, C
    Arnold, W
    Hulin, P
    Klein, RJ
    Renz, H
    Parak, FG
    Bergemann, C
    Lübbe, AS
    JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2001, 225 (1-2) : 187 - 193
  • [48] Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes
    Amr S. Abu Lila
    Tatsuhiro Ishida
    Hiroshi Kiwada
    Pharmaceutical Research, 2010, 27 : 1171 - 1183
  • [49] Targeting tumor vasculature: expanding the potential of DNA cancer vaccines
    Stefano Ugel
    John G. Facciponte
    Francesco De Sanctis
    Andrea Facciabene
    Cancer Immunology, Immunotherapy, 2015, 64 : 1339 - 1348
  • [50] Screening of peptides for drug delivery targeting irradiated tumor vasculature
    Fu, X
    Qu, S
    Hallahan, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S464 - S464